Context

Antiplatelet therapy represents the mainstay of treatment for patients undergoing percutaneous coronary intervention.1 However, an increased risk for gastrointestinal bleeding is associated with use of aspirin and clopidogrel. To reduce the bleeding risk, proton pump inhibitors (PPIs) are prescribed in combination with platelet inhibitors, a strategy that is recommended by existing consensus guidelines2 though no randomised trial has proved this. Recently, a pharmacodynamic drug–drug interaction has been shown for clopidogrel and omeprazole but not for pantoprazole.3 4 Whether this interaction has an impact on patient outcomes has not been investigated in a randomised trial.